PT  - JOURNAL ARTICLE
AU  - Roca, Bernardino
AU  - Roca, Manuel
TI  - The new oral anticoagulants: Reasonable alternatives to warfarin
AID  - 10.3949/ccjm.82a.14052
DP  - 2015 Dec 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 847--854
VI  - 82
IP  - 12
4099  - http://www.ccjm.org/content/82/12/847.short
4100  - http://www.ccjm.org/content/82/12/847.full
SO  - Cleve Clin J Med2015 Dec 01; 82
AB  - Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct activated factor X inhibitors) are increasingly being used in clinical practice. Compared with vitamin K antagonists, they are more convenient, do not require laboratory monitoring, have limited drug and food interactions, and have fixed dosages suitable for most patients. But the shortcomings of these agents can jeopardize their efficacy and increase the risk of bleeding. Their future role in preventing and treating thromboembolic disease will depend on building clinical experience, but current evidence indicates that they are reasonable alternatives to vitamin K antagonists.